Meeting
2022 ASCO Annual Meeting
A phase Ia/Ib study of intrathecal deferoxamine in patients with leptomeningeal metastases.
Authors
Jessica Wilcox
Memorial Sloan Kettering Cancer Center, New York, NY
Jessica Wilcox , Lisa R. Modelevsky , Tiffany Thomas , Serge Cremers , Robert J. Young , Anne S. Reiner , Katherine Panageas , Helena Alexandra Yu , Adrienne Ann Boire
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Central Nervous System Tumors
Track
Central Nervous System Tumors
Sub Track
Brain Metastases
Clinical Trial Registration Number
NCT05184816
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr TPS2074)
DOI
10.1200/JCO.2022.40.16_suppl.TPS2074
Abstract #
TPS2074
Poster Bd #
411b
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Annual Meeting
The clinical utility of a circulating tumor cell based cerebrospinal fluid assay in the diagnosis and molecular analysis of leptomeningeal disease in patients with metastatic non-small cell lung cancer.
First Author: Ramya Muddasani
Poster
2020 ASCO Virtual Scientific Program
Diagnosis of leptomeningeal metastasis (LM) through identification of circulating tumor cells (CTCs) in cerebrospinal fluid (CSF).
First Author: Kathleen Fenn
Poster
2015 ASCO Annual Meeting
Prospective validation of cerebrospinal fluid (CSF) circulating tumor cells (CTC) to diagnose leptomeningeal metastasis (LM) from epithelial tumors.
First Author: Xuling Lin
Poster
2013 ASCO Annual Meeting
Prognostic utility of neuraxis imaging in leptomeningeal metastasis (LM): A retrospective case series.
First Author: Marc C. Chamberlain